John Nuss Sells 12,675 Shares of Ventyx Biosciences (NASDAQ:VTYX) Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) insider John Nuss sold 12,675 shares of Ventyx Biosciences stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $97,851.00. Following the transaction, the insider directly owned 489,481 shares in the company, valued at approximately $3,778,793.32. The trade was a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Ventyx Biosciences Stock Performance

Shares of VTYX traded up $1.00 during mid-day trading on Friday, reaching $8.74. The stock had a trading volume of 2,836,325 shares, compared to its average volume of 2,101,134. The business has a fifty day moving average of $7.79 and a 200 day moving average of $4.44. The firm has a market cap of $623.69 million, a price-to-earnings ratio of -5.83 and a beta of 1.22. Ventyx Biosciences, Inc. has a 12 month low of $0.78 and a 12 month high of $10.55.

Ventyx Biosciences (NASDAQ:VTYX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.13. On average, research analysts forecast that Ventyx Biosciences, Inc. will post -2.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Ventyx Biosciences

Several large investors have recently added to or reduced their stakes in VTYX. Ashton Thomas Private Wealth LLC bought a new position in shares of Ventyx Biosciences in the second quarter worth about $71,000. Nuveen LLC purchased a new stake in Ventyx Biosciences in the 1st quarter valued at about $194,000. Ieq Capital LLC bought a new position in Ventyx Biosciences in the 1st quarter worth about $223,000. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Ventyx Biosciences by 8.4% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 945,206 shares of the company’s stock worth $2,023,000 after acquiring an additional 73,601 shares during the period. Finally, Affinity Asset Advisors LLC purchased a new position in shares of Ventyx Biosciences during the second quarter worth approximately $9,707,000. 97.88% of the stock is owned by institutional investors.

Analyst Ratings Changes

VTYX has been the topic of several recent analyst reports. HC Wainwright upgraded shares of Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 price objective on the stock in a research report on Wednesday, November 5th. Canaccord Genuity Group boosted their price target on shares of Ventyx Biosciences from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Ventyx Biosciences in a research report on Wednesday, October 8th. Oppenheimer increased their price target on Ventyx Biosciences from $9.00 to $14.00 and gave the company an “outperform” rating in a research note on Monday, October 27th. Finally, Wells Fargo & Company upped their price objective on Ventyx Biosciences from $11.00 to $14.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $15.50.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.